GNFT Genfit S.A.
USHealthcareAs of 2026-03-09 09:30
Why GNFT matters now
Genfit S.A. (GNFT) is a US stock in Healthcare. The latest InvestLog snapshot shows $8.95 with +4.07% on the session and $445.7M in market capitalization; recent performance reads 1-month +0.00% and YTD +48.42%.
The latest financial table shown here is Q2 2025, with revenue of $35.5M, net income of $-10.0M, and EPS of $-0.20. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -5.0%.
The latest indexable market news headline is "GENFIT: June 15, 2026 Combined Shareholders Meeting Results" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $13.00. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
-22.48
P/S
7.91
EV/EBITDA
-96.37
DCF Value
$-58.51
FCF Yield
-5.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
26.0%
Operating Margin
-84.3%
Net Margin
-127.4%
ROE
-596.4%
ROA
-54.4%
ROIC
-41.0%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2025 | $35.5M | $-10.0M | $-0.20 |
| Q4 2024 | $5.9M | $-28.8M | $-0.58 |
| FY 2024 | $67.0M | $1.5M | $0.03 |
| Q2 2024 | $61.1M | $30.3M | $0.50 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$13.00
Target (Median)
$13.00
Target Range
$13.00 - $13.00
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
FR
Exchange
—
Beta
0.87
Genfit S.A. operates as a biopharmaceutical company dedicated to discovering and advancing novel therapeutic candidates and diagnostic solutions for a range of metabolic and liver-related diseases. Its most advanced drug candidate, Elafibranor, is currently undergoing Phase 3 clinical evaluation for the treatment of primary biliary cholangitis (PBC). Beyond therapeutics, Genfit is also developing its NIS4 technology, designed to aid in the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis. The company's pipeline further encompasses GNS561, which is in Phase 1b/2 trials for cholangiocarcinoma (CCA), and Nitazoxanide, undergoing Phase 1 evaluation as a potential therapy for acute-on-chronic liver failure. Genfit has established strategic partnerships, including a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test. Additionally, it collaborates with Genoscience Pharma to jointly develop and market the investigational treatment GNS561 for CCA. Founded in 1999, Genfit S.A. is headquartered in Loos, France.